BCLI vs. ITRM, RAPT, PEPG, TPST, DTIL, CLNN, MDCX, ELEV, ANVS, and CASI
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Iterum Therapeutics (ITRM), RAPT Therapeutics (RAPT), PepGen (PEPG), Tempest Therapeutics (TPST), Precision BioSciences (DTIL), Clene (CLNN), Medicus Pharma (MDCX), Elevation Oncology (ELEV), Annovis Bio (ANVS), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry.
Brainstorm Cell Therapeutics vs.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends.
Iterum Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Brainstorm Cell Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.
14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Iterum Therapeutics had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for Iterum Therapeutics and 1 mentions for Brainstorm Cell Therapeutics. Iterum Therapeutics' average media sentiment score of 0.99 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the news media.
Brainstorm Cell Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 1,634.10%. Iterum Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 234.45%. Given Brainstorm Cell Therapeutics' higher probable upside, equities research analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Iterum Therapeutics.
Brainstorm Cell Therapeutics received 150 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. However, 62.95% of users gave Iterum Therapeutics an outperform vote while only 60.50% of users gave Brainstorm Cell Therapeutics an outperform vote.
Summary
Iterum Therapeutics beats Brainstorm Cell Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCLI) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BCLI Stock Alerts